Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02325739
Other study ID # CFGF401X2101
Secondary ID 2014-002929-35
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date December 29, 2014
Est. completion date May 30, 2019

Study information

Verified date November 2020
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Estimate the maximum tolerated dose and/or recommended phase II dose and efficacy of FGF401 as single agent and in combination with PDR001 in patients with hepatocellular carcinoma and as single agent in patients with other solid malignancies based on RECIST 1.1.


Description:

The primary objectives of this study were in 2 parts: Phase l & Phase II. The study included different periods starting by molecular pre-screening (applicable for all subjects enrolled under protocol versions 00 to 03, or applicable only for Phase I and Group 3 in Phase II of FGF401 single agent, for subjects enrolled under protocol version 04), Screening, Treatment, End of Treatment, Disease progression follow-up (if applicable), Safety follow-up and then ended by survival follow-up period In the Phase I part, subjects with HCC or other advanced solid tumors characterized by positive FGFR4 and KLB expression were enrolled and treated with FGF401 as a single agent or in combination with PDR001. Subjects in this phase were dosed under fasted or fed conditions. In the Phase 2 part, subjects with advanced HCC or other solid tumors bearing positive FGFR4 and KLB expression were enrolled into three groups (Group 1: HCC subjects from Asian countries; Group 2: HCC subjects from non-Asian countries; Group 3: Subjects with other solid malignancies regardless of geography) to assess the preliminary anti-tumor activity of FGF401 in Phase ll. This Phase II part investigated the anti-tumor activity of FGF401 single agent and in combination with PDR001. Each group within the Phase II dose expansion part targeted a different number of subjects. Group 1 and Group 2 planned to enroll around 40 subjects each and Group 3 planned to enroll approximately 20 subjects. Subjects in this phase were dosed under fasted conditions. Oral FGF401 was administered on a continuous once daily (QD) dosing regimen for both FGF401 single agent and in combination with PDR001 parts. Intravenous PDR001 was administered in a fixed dosing regimen of 300 mg iv every three weeks as per protocol until subject experienced unacceptable toxicity, progressive disease and/or treatment was discontinued at the discretion of the Investigator or withdrawal of consent. Because the enrollment of new subjects in this study was halted for business reason on 03-Jul-2018 early enrollment termination was declared following the initial halt of enrollment once the global last subject last visit was achieved as per protocol, and consequently the phase II part of the FGF401+PDR001 combination did not start, none of the planned analyses related to the phase II part of the FGF401+PDR001 combination arm were performed. Duration of treatment: Subjects could continue study treatment until they experienced any of the following: Disease progression (radiologically documented according to RECIST v1.1) as assessed by the Investigator, unacceptable toxicity, & treatment was discontinued at the discretion of the Investigator or the subject. Subjects who permanently discontinued the study treatment for any reason other than disease progression or withdrawal of consent had to continue efficacy assessments as scheduled in the protocol until the time of disease progression.


Recruitment information / eligibility

Status Completed
Enrollment 172
Est. completion date May 30, 2019
Est. primary completion date May 30, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. ECOG Performance Status = 1 2. Presence of at least one measurable lesion according to RECIST v1.1. c-i) FGF401 single agent-Phase I and Phase II, Group 3: Patients with HCC or advanced solid tumors, who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists. c-ii) FGF401 single agent-Phase II, Groups 1 and 2: HCC patients previously treated with sorafenib for advanced HCC with documented disease progression during or after discontinuation of sorafenib treatment, or intolerance to sorafenib treatment c-iii) FGF401 in combination with PDR001:Advanced HCC patients who have received up to 2 previous lines of systemic treatment and one treatment must have included sorafenib with documented disease progression during or after discontinuation of sorafenib treatment, or intolerance to sorafenib treatment Exclusion Criteria: 1. Previous treatment with a selective FGF19-FGFR4 targeted therapy and/or pan-FGFR inhibitor. 2. Symptomatic CNS metastases which are neurologically unstable or requiring increasing doses of steroids to control their CNS disease. 3. Patient having out of range laboratory values defined as: - Hematology Hemoglobin = 9 g/dL (SI Units: 90 g/L) Platelet count < 75000/mm3 Absolute neutrophil count (ANC) < 1500/mm3 - Chemistry Total bilirubin = 2 mg/dL AST and/or ALT > 3 x ULN Serum creatinine > 1.5 x ULN and/or creatinine clearance = 45 mL/min - Coagulation: PT > 4 seconds more than ULN or INR > 1.7 4. Pregnant or nursing (lactating) women. Other protocol-defined Inclusion/Exclusion criteria may apply.

Study Design


Intervention

Drug:
FGF401
FGF401 is a FGFR4 inhibitor.
Biological:
PDR001
PDR001 is a humanized anti-PD1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2

Locations

Country Name City State
China Novartis Investigative Site Shanghai Shanghai
France Novartis Investigative Site Lille Cedex
France Novartis Investigative Site Montpellier cedex 5
France Novartis Investigative Site Pessac Cedex
France Novartis Investigative Site Rennes Cedex Ille Et Vilaine
France Novartis Investigative Site Toulouse Cedex 9
Germany Novartis Investigative Site Essen
Germany Novartis Investigative Site Hannover
Germany Novartis Investigative Site Heidelberg
Germany Novartis Investigative Site Wuerzburg
Hong Kong Novartis Investigative Site Hong Kong
Italy Novartis Investigative Site Milano MI
Italy Novartis Investigative Site Modena MO
Japan Novartis Investigative Site Chuo ku Tokyo
Japan Novartis Investigative Site Osaka Sayama Osaka
Korea, Republic of Novartis Investigative Site Seoul Korea
Korea, Republic of Novartis Investigative Site Seoul
Korea, Republic of Novartis Investigative Site Seoul
Singapore Novartis Investigative Site Singapore
Spain Novartis Investigative Site Barcelona Catalunya
Spain Novartis Investigative Site Barcelona Catalunya
Spain Novartis Investigative Site Madrid
Taiwan Novartis Investigative Site Tainan Taiwan ROC
Taiwan Novartis Investigative Site Taipei
United States Massachusetts General Hospital Oncology Dept Boston Massachusetts
United States University of Texas MD Anderson Cancer Center Houston Texas
United States University of California at Los Angeles Santa Monica Location Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  China,  France,  Germany,  Hong Kong,  Italy,  Japan,  Korea, Republic of,  Singapore,  Spain,  Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Dose-limiting Toxicity (DLT): Phase I Only A dose-limiting toxicity was defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurred within the evaluation period of DLTs and met any of the criteria listed. The estimation of the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of the treatment was based upon the estimation of the probability of DLT during the evaluation period for subjects in the dose determining set (DDS). A subject with multiple occurrences of a DLT under one treatment is counted only once in the AE category for that treatment. A subject with multiple DLTs within a primary system organ class is counted only once in the total row. Cycle 1 (C1) (21 days) for FGF401 single agent, Cycle 1 and Cycle 2 (C2) (42 days) for FGF401 and PDR001 combination
Primary Time to Progression (TTP): Group 1 & Group 2 (Phase II Only) TTP is defined as the date of start treatment to the date of event defined as the first documented progression or death due to underlying cancer. Method used was Kaplan-Meier analysis.
Group 1: HCC subjects form Asian countries; Group 2: HCC subjects form non-Asian countries
approx. 4.5 years
Primary Overall Response Rate (ORR) Based on Local Assessment: Group 3 (Phase II Only) ORR is defined as the percentage of patients with a best overall response of CR or PR (RECIST v1.1).
FGF401 single agent-Phase II part - Group 3 (non-HCC, other solid tumors).
approx. 4.5 years
Secondary Best Overall Response (BOR) by Investigator Assessment: Phase I and Phase II BOR is the best response recorded from the start of the treatment until disease progression/recurrence. BOR is determined according to: complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) and unknown. approx. 4.5 years
Secondary Overall Response Rate (ORR) by Investigator Assessment Phase I and FGF401 Single Agent Phase II Groups 1 & 2 ORR is defined as the proportion of patients with a best overall response of CR or PR (RECIST v1.1).
Phase I part and FGF401 single agent Phase II Group 1 (HCC, Asians) and Group 2 (HCC, non-Asians)
approx. 4.5 years
Secondary Disease Control Rate (DCR) by Local Investigator Assessment Phase I and FGF401 Single Agent Phase II Groups 1, 2 & 3 DCR is the percentage of participants with a best overall response of CR or PR or SD per local assessment according to RECIST v1.1. Phase I part and FGF401 single agent Phase II Group 1 (HCC, Asians) and Group 2 (HCC, non-Asians) and Group 3 (non-HCC, other solid tumors). approx. 4.5 years
Secondary Time to Progression (TTP) in Participants Dosed With Single Agent FGF401 120 mg (Fasted & Fed) & With Combination FGF401 120 mg + PDR001 300 mg Q3W (Phase I) TTP is defined as the date of start treatment to the date of event defined as the first documented progression or death due to underlying cancer. Method used was Kaplan-Meier analysis. approx. 4.5 years
Secondary Overall Survival (OS) in Participants Dosed With Single Agent FGF401 120 mg (Fasted & Fed) and in Participants Dosed With Combination FGF401 120 mg and PDR001 300 mg Q3W (Phase I & II) Overall survival (OS) is defined as the time from date of start of treatment to date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last known date patient alive. Method used was Kaplan-Meier analysis. start of treatment to death, up to about 53 months
Secondary Progression-free Survival (PFS) - FGF401 Single Agent Phase II: Group 3 Progression-free survival (PFS) is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment. Group 3 - non-HCC, other solid tumors. Method used was Kaplan-Meier analysis. 4.5 years
Secondary Presence and/or Concentration of Anti-PDR001 Antibodies Serum PDR001 concentrations as well as immunogenicity analysis were performed for all subjects receiving PDR001. Treatment-induced ADA-positive percentage was based on percentage subjects ADA-negative at baseline. Treatment-boosted ADA-positive percentage was based on subjects ADA-positive at baseline. Day 1 of Cycle 1 to 6, approx. 10 months after C1D1 and 150-day safety follow up (FU)
Secondary Cmax of PDR001 in Combination With FGF401: Phase I Cmax is the maximum (peak) observed plasma drug concentration (mass x volume-1) After the first dosing sample collection was at: C1D1 0hr , C1D1 1hr, C1D8 168hr, C1D15 336hr, C2D1 504hr; each cycle is 21 days
Secondary AUClast and AUCtau of PDR001 in Combination of FGF401: Phase I AUClast: The AUC from time zero to the last measurable concentration sampling time (Tlast) (mass x time x volume-1)
AUCtau (AUC0 504h): The AUC calculated to the end of a dosing interval (tau) (amount x time x volume-1)
After the first dosing sample collection was at: C1D1 0hr , C1D1 1hr, C1D8 168hr, C1D15 336hr, C2D1 504hr; each cycle is 21 days
Secondary T1/2 of PDR001: Phase I Due to the sparse PK sampling designed from PDR001, the PDR001 concentration data was insufficient for accurate estimation of secondary PK parameters including T1/2. After the first dosing sample collection was at: C1D1 0hr , C1D1 1hr, C1D8 168hr, C1D15 336hr, C2D1 504hr; each cycle is 21 days
Secondary Cmax of FGF401: Phase I Cmax is the maximum (peak) observed plasma drug concentration (mass x volume-1) C1D1 (0 hour (h), 0.5h, 1h, 2h, 3h, 4h, 6h, 12h, 24h), C1D8 (0h, 0.5h, 1h, 2h, 3h, 4h, 6h, 12h, 24h), and C2D1 (0h, 0.5h, 1h, 2h, 3h, 4h, 6h, 12h, 24h)
Secondary Cmax of FGF401 in Combination With PDR001: Phase I Cmax is the maximum (peak) observed plasma drug concentration (mass x volume-1) C1D1 (0h, 0.5h, 1h, 2h, 3h, 4h, 6h, 12h, 24h)
Secondary AUCinf, AUClast & AUCtau of FGF401: Phase I AUCinf: The AUC from time zero to infinity (mass x time x volume-1)
AUClast: The AUC from time zero to the last measurable concentration sampling time (Tlast) (mass x time x volume-1)
AUCtau: The AUC calculated to the end of a dosing interval (tau) (amount x time x volume-1)
C1D1 (0h, 0.5h, 1h, 2h, 3h, 4h, 6h, 12h, 24h), C1D8 (0h, 0.5h, 1h, 2h, 3h, 4h, 6h, 12h, 24h), and C2D1 (0h, 0.5h, 1h, 2h, 3h, 4h, 6h, 12h, 24h)
Secondary AUCinf, AUClast & AUCtau of FGF401 in Combination With PDR001: Phase I AUCinf: The AUC from time zero to infinity (mass x time x volume-1)
AUClast: The AUC from time zero to the last measurable concentration sampling time (Tlast) (mass x time x volume-1)
AUCtau: The AUC calculated to the end of a dosing interval (tau) (amount x time x volume-1)
C1D1 (0h, 0.5h, 1h, 2h, 3h, 4h, 6h, 12h, 24h)
Secondary T1/2 of FGF401: Phase I The elimination half-life associated with the terminal slope ( z) of a semi logarithmic concentration-time curve (time). C1D1 (0h, 0.5h, 1h, 2h, 3h, 4h, 6h, 12h, 24h), C1D8 (0h, 0.5h, 1h, 2h, 3h, 4h, 6h, 12h, 24h), and C2D1 (0h, 0.5h, 1h, 2h, 3h, 4h, 6h, 12h, 24h)
See also
  Status Clinical Trial Phase
Completed NCT03007212 - Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis Phase 4
Terminated NCT03236649 - The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects Phase 3
Withdrawn NCT04044326 - The Safety and Efficacy of Spherical Microwave Ablation for the Treatment of Malignant Liver Tumors N/A
Recruiting NCT04687969 - Multimodal Machine Learning Characterization of Solid Tumors
Completed NCT02562755 - Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Phase 3
Withdrawn NCT02406508 - Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC Phase 2
Completed NCT01972672 - The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma Phase 2
Completed NCT01247298 - A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma Phase 0
Completed NCT03735628 - An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors Phase 1
Completed NCT02188901 - Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study N/A
Active, not recruiting NCT04522908 - Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function Phase 2
Terminated NCT01433016 - Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI Phase 2
Withdrawn NCT04465734 - A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC Phase 3
Recruiting NCT05057013 - HMBD-001 in Advanced HER3 Positive Solid Tumours Phase 1/Phase 2
Active, not recruiting NCT03753659 - IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) Phase 2
Terminated NCT03144661 - An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Phase 1
Not yet recruiting NCT01821482 - A Study of DC-CIK to Treat Hepatocellular Carcinoma Phase 2
Completed NCT03516071 - A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC Phase 2
Completed NCT01761266 - A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma Phase 3
Not yet recruiting NCT06345001 - A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer Phase 1